MedTrace Logo

REward Processing And Citalopram Study

NCT06017037 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-08-30

No results posted yet for this study

Summary

The goal of this experimental medicine study is to examine the effect of increasing serotonin on reward processing in healthy volunteers. The main questions it aims to answer are:

1. Does a subacute increase in serotonin influence the activation regions during reward learning
2. Does a subacute increase in serotonin influence behavioural markers of reward valuation (effort task), responsiveness (taste task) and learning (learning task)

Participants will be:

given a 7-day course of the selective serotonin reuptake inhibitor, citalopram. undergo behavioural testing complete a reward learning task whilst undergoing fMRI

Researchers will compare results against a placebo group.

Conditions

  • Anhedonia

Interventions

DRUG

Citalopram 20mg

Citalopram 20mg tablets, encapsulated to aid blinding. To take per oral once daily for 7-9 days

DRUG

Placebo

Lactose monohydrate tablets encapsulated to aid blinding. To take per oral once daily for 7-9 days

Sponsors & Collaborators

  • University of Oxford

    lead OTHER

Principal Investigators

  • Catherine Harmer, PhD · University of Oxford

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-19
Primary Completion
2024-05-01
Completion
2024-05-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06017037 on ClinicalTrials.gov